Mason Carrico
Stock Analyst at Stephens & Co.
(3.46)
# 818
Out of 5,154 analysts
77
Total ratings
44.78%
Success rate
7.05%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $198.13 | +18.61% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $1.38 | +44.93% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $75.74 | +0.34% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $8.96 | +22.77% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $33.71 | +98.75% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $124.62 | -15.74% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $20.81 | -32.72% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $17.89 | +123.59% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $107.73 | +6.75% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $33.85 | +32.94% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $91.20 | -39.69% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.22 | +42.18% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $18.46 | -7.91% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $70.41 | -26.15% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $5.15 | +288.35% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $27.12 | +51.18% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $198.13
Upside: +18.61%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $1.38
Upside: +44.93%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $75.74
Upside: +0.34%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $8.96
Upside: +22.77%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $33.71
Upside: +98.75%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $124.62
Upside: -15.74%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $20.81
Upside: -32.72%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $17.89
Upside: +123.59%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $107.73
Upside: +6.75%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $33.85
Upside: +32.94%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $91.20
Upside: -39.69%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.22
Upside: +42.18%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $18.46
Upside: -7.91%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $70.41
Upside: -26.15%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $5.15
Upside: +288.35%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $27.12
Upside: +51.18%